Comparative Efficacy, Hematologic Safety, and Treatment Persistence of FDA-Approved Janus Kinase Inhibitors in Myelofibrosis: Integrating the 2026 Approval of Once-Daily Ruxolitinib XR—A Systematic Review and Bayesian Network Meta-Analysis (SOHO 2026) - Sep 1, 2026 - Abstract #MPN-984; Location: LEVEL 3, HALL B3; "For spleen volume reduction ≥35% at Week 24, ruxolitinib immediate release (IR)/XR demonstrated the highest efficacy (OR, 44.2; 95% credible interval [CrI], 14.1–118.5; surface under the cumulative ranking curve [SUCRA] = 0.95), followed by fedratinib (OR, 32.1; 95% CrI, 9.1–90.3; SUCRA = 0.81), momelotinib (OR, 18.4; 95% CrI, 6.2–49.7; SUCRA = 0.63), and pacritinib (OR, 11.6; 95% CrI, 3.4–31.2; SUCRA = 0.49). Ruxolitinib XR maintained superior efficacy and treatment persistence, whereas momelotinib and pacritinib demonstrated phenotype-specific safety advantages, supporting a personalized therapeutic approach in myelofibrosis, with overall low risk of bias across included trials using RoB 2.0."
Retrospective data • Review • Myelofibrosis • Oncology
|
|
Rakhshanda Khan MBBS 1; Sangeetha Gandhi MBBS 2; Saloni Jindal 3; Haroon Alamy MD 4; Yashasvi Sanghvi 5; Swathi Ramesh 6; Harshawardhan Dhanraj Ramteke MBBS 7; Dineshbaba Murugavel MBBS 8
|